Pegsitacianine is an actionable marker to identify tumor tissue for real-time surgical imaging and validates the use of the ON-BOARD™ platform for precision tumor targeting. Phase 2 study results in patients with peritoneal metastases demonstrated that pegsitacianine was well tolerated with minimal adverse effects, and that 50% of evaluable patients showed clinical benefit during cytoreductive surgery through the identification of pathology-confirmed disease resected with pegsitacianine guidance. Based upon this data, the Food and Drug Administration granted pegsitacianine Breakthrough Therapy Designation in this indication.